查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1629873

全球呼吸护理设备市场 - 2025-2033

Global Respiratory Care Devices Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2023年，全球呼吸护理设备市场规模达228.5亿美元，预计2033年将达到405.9亿美元，2025-2033年预测期间复合年增长率为6.4%。

呼吸照护装置是用于支持和改善呼吸困难或肺部相关疾病患者的呼吸功能的医疗设备。它们用于预防、诊断、监测和治疗气喘、慢性阻塞性肺病、睡眠呼吸中止症和急性呼吸窘迫症候群等呼吸系统疾病。主要类型包括呼吸器等治疗设备、肺活量计等诊断工具、脉搏血氧仪等监测设备。这些设备广泛应用于医院、诊所和家庭护理场所，以改善患者的治疗效果和生活品质。

市场动态：

驱动程式和限制

呼吸道疾病盛行率上升

全球呼吸照护设备市场是由慢性阻塞性肺病、气喘、睡眠呼吸中止症和急性感染等呼吸系统疾病的增加所推动的。空气污染、吸烟和人口老化等因素导致了这些状况。这些疾病需要长期管理和先进的医疗支援。 COVID-19 大流行凸显了呼吸护理设备在管理急性呼吸窘迫方面的重要性，从而提高了人们的意识和投资。呼吸系统疾病负担的增加鼓励了便携式、用户友好型设备的创新，迎合了家庭护理的趋势。这种流行加速了市场成长，并强调了全球对可获得、高效且负担得起的呼吸护理解决方案的需求。

例如，根据非传染性疾病联盟的说法，慢性呼吸道疾病 (CRD) 是一种与肺部相关的疾病，在全世界造成显着的发病率和死亡率。常见的 CRD 包括慢性阻塞性肺病 (COPD)、气喘、肺癌和职业性肺病。这些疾病影响全球至少 5,500 亿成年人，占所有死亡人数的 7%。肺癌每年导致另外 14 亿人死亡。五岁以下儿童特别容易受到肺部疾病的影响，包括肺炎等急性传染病和气喘等慢性疾病。气喘是最常见的慢性病，​​影响全球 14% 的儿童。 1990 年至 2017 年间，CRD 的盛行率增加了 40%，但与其他非传染性疾病相比，它们受到较少的关注。

设备操作的复杂性

由于设备操作的复杂性，特别是呼吸器、CPAP 机和製氧机等先进设备，全球呼吸护理设备市场面临严重限制。这些设备需要专业知识才能正确设置、使用和维护，由于对家庭护理环境中的医疗保健专业人员、护理人员和患者的培训不足，这可能具有挑战性。

这项挑战在医疗保健专业人员可能缺乏专业知识且家庭医疗保健环境往往缺乏适当支持的资源匮乏地区更为明显。对监控和校准的持续需求增加了复杂性，需要熟练的劳动力来确保最佳的设备功能。这些操作困难可能会阻碍呼吸护理设备的采用，特别是在服务不足的地区，从而限制了市场的成长潜力。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 呼吸道疾病盛行率上升
    • 限制
      • 设备操作的复杂性
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章：依产品类型

  • 治疗设备
    • 持续性呼吸道正压通气 (CPAP) 设备
    • 双水平气道正压通气 (BiPAP) 装置
    • 呼吸器
    • 雾化器
    • 吸入器（定量吸入器、干粉吸入器）
    • 制氧机
  • 监控设备
    • 脉搏血氧仪
    • 二氧化碳描记器
    • 气体分析仪
  • 诊断设备
    • 肺活量计
    • 多导睡眠监测设备
    • 峰值流量计
  • 耗材及配件
    • 呼吸迴路
    • 鼻插管
    • 面具
    • 管
    • 过滤器

第 7 章：按申请

  • 慢性阻塞性肺病（COPD）
  • 气喘
  • 阻塞性睡眠呼吸中止症 (OSA)
  • 呼吸窘迫症候群
  • 其他的

第 8 章：最终用户

  • 医院和诊所
  • 家庭护理设置
  • 门诊手术中心

第 9 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • Philips Respironics (Philips Healthcare)
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • ResMed Inc.
  • Medtronic Plc
  • Fisher & Paykel Healthcare
  • Invacare Corporation
  • Dragerwerk AG & Co. KGaA
  • GE Healthcare
  • Getinge AB
  • Teleflex Incorporated
  • Hamilton Medical AG

第 12 章：附录

简介目录
Product Code: MD8903

The global respiratory care devices market reached US$ 22.85 billion in 2023 and is expected to reach US$ 40.59 billion by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033.

Respiratory care devices are medical equipment used to support and improve the respiratory functions of patients with breathing difficulties or lung-related conditions. They are used for the prevention, diagnosis, monitoring, and treatment of respiratory disorders like asthma, COPD, sleep apnea, and ARDS. Key types include therapeutic devices like ventilators, diagnostic tools like spirometers, and monitoring devices like pulse oximeters. These devices are widely used in hospitals, clinics, and home care settings to improve patient outcomes and quality of life.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Respiratory Diseases

The global respiratory care devices market is driven by the rise in respiratory diseases like COPD, asthma, sleep apnea, and acute infections. Factors like air pollution, smoking, and aging populations contribute to these conditions. Long-term management and advanced medical support are needed for these diseases. The COVID-19 pandemic highlighted the importance of respiratory care devices in managing acute respiratory distress, leading to increased awareness and investment. The rising burden of respiratory diseases has encouraged innovation in portable, user-friendly devices, catering to home-based care trends. This prevalence accelerates market growth and emphasizes the need for accessible, efficient, and affordable respiratory care solutions globally.

For instance, according to NCD Alliance, Chronic respiratory diseases (CRDs) are lung-related diseases that cause significant morbidity and mortality worldwide. Common CRDs include COPD, asthma, lung cancer, and occupational lung diseases. These diseases affect at least 550 Billion adults globally and account for 7% of all deaths. Lung cancer contributes to another 1.4 Billion deaths annually. Children under five years of age are particularly affected by lung diseases, including acute infectious diseases like pneumonia and chronic conditions like asthma. Asthma is the most common chronic condition, affecting 14% of children globally. The prevalence of CRDs has increased by 40% between 1990 and 2017, but they have received less attention than other NCDs.

Complexity of Device Operation

The global respiratory care devices market faces significant restraint due to the complexity of device operation, especially advanced devices like ventilators, CPAP machines, and oxygen concentrators. These devices require specialized knowledge for proper setup, usage, and maintenance, which can be challenging due to inadequate training for healthcare professionals, caregivers, and patients in home care settings.

This challenge is more pronounced in low-resource regions where healthcare professionals may lack expertise, and home healthcare settings often lack proper support. The constant need for monitoring and calibration adds to the complexity, requiring a skilled workforce to ensure optimal device functionality. These operational difficulties can discourage the adoption of respiratory care devices, especially in underserved areas, limiting the market's growth potential.

Segment Analysis

The global respiratory care devices market is segmented based on product type, application, end user and region.

Product type:

Therapeutic Devices segment is expected to dominate the respiratory care devices market share

The therapeutic devices segment holds a major portion of the respiratory care devices market share and is expected to continue to hold a significant portion of the respiratory care devices market share during the forecast period.

Therapeutic devices are crucial in managing chronic and acute respiratory conditions, such as COPD, asthma, sleep apnea, and respiratory distress syndrome. The global respiratory care devices market is growing due to factors like air pollution, smoking, and aging populations. Technological advancements, such as portable oxygen concentrators and smart CPAP machines, have enhanced patient convenience and compliance. The COVID-19 pandemic highlighted the importance of ventilators and oxygen therapy, leading to increased awareness and investment in therapeutic devices. The trend towards home-based care and reducing healthcare costs has driven the adoption of these devices, ensuring long-term management of respiratory diseases outside traditional healthcare settings.

For instance, in September 2024, ResMed has launched its AirTouch N30i continuous positive airway pressure (CPAP) mask, designed to provide a comfortable sleep experience for users with sleep apnea. The mask features a fabric-wrapped frame and a soft, breathable, moisture-wicking design for optimal comfort. It builds upon ResMed's previous masks to combine softness, breathability, and a high-performance seal, making it easier for people to start and stick with CPAP therapy.

Moreover, in February 2024, ResMed has introduced its AirCurve 11 series, a bilevel device that uses inspiratory and expiratory positive airway pressure (IPAP) to treat sleep apnea. The AirCurve 11 VAuto is a bilevel PAP that provides higher pressure during inhalation and lower pressure during exhalation, allowing the device to align more closely with natural breathing patterns.

Application:

Chronic Obstructive Pulmonary Disease (COPD) segment is the fastest-growing segment in respiratory care devices market share

The Chronic Obstructive Pulmonary Disease (COPD) segment is the fastest-growing segment in the respiratory care devices market share and is expected to hold the market share over the forecast period.

Chronic Obstructive Pulmonary Disease (COPD) is a major global health concern, causing significant morbidity and mortality. The condition, primarily caused by smoking, air pollution, occupational hazards, and genetic factors, has led to a surge in demand for respiratory care devices like oxygen concentrators, nebulizers, and ventilators. These devices are crucial for managing symptoms, improving oxygenation, and enhancing patient quality of life. The growing awareness of early diagnosis and treatment, coupled with technological advancements, has fueled the adoption of portable and home-based solutions for COPD management. The economic burden of hospitalizations due to severe COPD exacerbations has shifted focus towards preventive and long-term care, driving market expansion globally.

For instance, in March 2023, Pulmonologists at the University of Cincinnati have developed a new breathing device called PEP Buddy, which not only improves breathlessness and quality of life for COPD patients but also benefits those dealing with stress and anxiety, as well as those practicing mindfulness, meditation, or yoga. The device, created by Muhammad Ahsan Zafar and Ralph Panos, was published in the journal Respiratory Care. Zafar is an associate professor in the Department of Pulmonary Critical Care and Sleep Medicine, Panos is a professor emeritus in pulmonary and critical care.

Geographical Analysis

North America is expected to hold a significant position in the respiratory care devices market share

North America holds a substantial position in the respiratory care devices market and is expected to hold most of the market share due to the novel product launches, high prevalence of chronic diseases like COPD, asthma, and sleep apnea, driven by lifestyle factors and an aging population. The region's healthcare infrastructure supports the widespread use of advanced respiratory care devices, such as ventilators, nebulizers, and CPAP machines. Government and private insurance programs offer favorable reimbursement policies, reducing financial burdens and enabling broader access. The region is also a hub for innovation, with companies investing in portable, wireless, and AI-powered devices for home-based care.

For instance, in December 2024, University Medical Devices (UMD) has launched its first specimen collection method, MicroWash, a comfortable and sensitive nasal lavage device designed as a less invasive alternative to nasal swabs during the COVID-19 pandemic.

Moreover, in July 2023, Emerson has introduced the ASCO Series 588 Stationary Oxygen Concentrator Manifold, a turnkey solution for the healthcare industry. This manifold optimizes respiratory therapy device designs, accelerates product speed to market, and improves energy efficiency, lifespan, and reliability of oxygen concentrators, ensuring they are readily available and reliable for patients.

Europe is growing at the fastest pace in the respiratory care devices market

Europe holds the fastest pace in the respiratory care devices market and is expected to hold most of the market share due to the aging population, environmental factors, and the healthcare system's focus on early diagnosis and treatment. The adoption of novel advanced respiratory care devices is encouraged by reimbursement frameworks and the growing trend towards home-based care solutions. Countries like Germany, France, and the UK drive innovation and market growth due to their strong clinical research capabilities and supportive regulatory environments.

For instance, in October 2024, Chiesi UK and Ireland and Health Innovation Manchester have launched the iMprovIng outcomes in respiratory care Greater Manchester (MISSON) project, which will introduce clinically-validated LungHealth software to up to 150 GP practices in Greater Manchester over a two-year period. The software uses digital technology, embedded algorithms, and patient medical records to provide computer-guided consultations for asthma and COPD annual reviews.

Moreover, in October 2024, The LungHealth software, developed by Health Innovation Manchester and Chiesi UK and Ireland, is being introduced to 150 GP practices in Greater Manchester over a two-year period. The software uses embedded algorithms and patients' medical records to provide computer-guided consultations for asthma and COPD annual reviews. The software can be carried out remotely or face-to-face, and also provides clinical prompts to upskill healthcare professionals. The MISSION project aims to evaluate the technology's effectiveness in improving the quality, effectiveness, and consistency of reviews, thereby reducing the impact of asthma and COPD exacerbations on patients and the NHS.

Competitive Landscape

The major global players in the respiratory care devices market include Koninklijke Philips N.V.; Fitbit (Google); Garmin Ltd.; Medtronic; Omron; Withings; VitalConnect; Polar Electro; Sotera, Inc.; INVIZA Corporation; Dexcom, Inc.; GE HealthCare; CONTEC MEDICAL SYSTEMS CO., LTD; Nanowear Inc. among others.

Emerging Players

The emerging players in the respiratory care devices market include Vivos Therapeutics, Omron Healthcare, AirSep Corporation and among others.

Key Developments

  • In February 2024, Getinge, a global medical technology leader, has introduced the Servo-c mechanical ventilator, a revolutionary device designed to address the diverse respiratory needs of patients in India, both pediatric and adult. The ventilator is designed to provide lung-protective therapeutic tools, catering to the evolving healthcare landscape. Getinge aims to empower hospitals with advanced healthcare solutions without compromising on quality, focusing on accessibility and affordability.
  • In March 2023, Vitalograph, a respiratory diagnostic device developer, has launched its VitaloPFT Pulmonary Function Testing Series for secondary care use. The launch took place at the Arab Health Exhibition in Dubai, supported by Irish minister for trade promotion and digital transformation Dara Calleary TD and Irish ambassador Alison Milton. The VitaloPFT Series provides advanced respiratory diagnostic solutions for hospitals and other secondary care units requiring complex pulmonary function testing.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global respiratory care devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Prevalence of Respiratory Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Complexity of Device Operation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Product type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
    • 6.1.2. Market Attractiveness Index, By Product type
  • 6.2. Therapeutic Devices*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Continuous Positive Airway Pressure (CPAP) Devices
    • 6.2.4. Bi-level Positive Airway Pressure (BiPAP) Devices
    • 6.2.5. Ventilators
    • 6.2.6. Nebulizers
    • 6.2.7. Inhalers (Metered-Dose Inhalers, Dry Powder Inhalers)
    • 6.2.8. Oxygen Concentrators
  • 6.3. Monitoring Devices
    • 6.3.1. Pulse Oximeters
    • 6.3.2. Capnographs
    • 6.3.3. Gas Analyzers
  • 6.4. Diagnostic Devices
    • 6.4.1. Spirometers
    • 6.4.2. Polysomnography Devices
    • 6.4.3. Peak Flow Meters
  • 6.5. Consumables and Accessories
    • 6.5.1. Breathing Circuits
    • 6.5.2. Nasal Cannulas
    • 6.5.3. Masks
    • 6.5.4. Tubes
    • 6.5.5. Filters

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Chronic Obstructive Pulmonary Disease (COPD)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Asthma
  • 7.4. Obstructive Sleep Apnea (OSA)
  • 7.5. Respiratory Distress Syndrome
  • 7.6. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals & Clinics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Home Care Settings
  • 8.4. Ambulatory Surgical Centers

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Philips Respironics (Philips Healthcare)*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. ResMed Inc.
  • 11.3. Medtronic Plc
  • 11.4. Fisher & Paykel Healthcare
  • 11.5. Invacare Corporation
  • 11.6. Dragerwerk AG & Co. KGaA
  • 11.7. GE Healthcare
  • 11.8. Getinge AB
  • 11.9. Teleflex Incorporated
  • 11.10. Hamilton Medical AG

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1 About Us and Services
  • 12.2 Contact Us